HC Wainwright Lowers Korro Bio (NASDAQ:KRRO) Price Target to $100.00

Korro Bio (NASDAQ:KRRO) had its target price reduced by analysts at HC Wainwright from $115.00 to $100.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($2.17) EPS and FY2026 earnings at ($8.32) EPS.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald upgraded shares of Korro Bio to a “strong-buy” rating in a research note on Tuesday, April 29th. Royal Bank of Canada cut their target price on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, March 19th. Oppenheimer started coverage on Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price target on the stock. Finally, Chardan Capital began coverage on Korro Bio in a report on Wednesday, April 16th. They set a “buy” rating and a $25.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Korro Bio has an average rating of “Buy” and an average target price of $112.75.

Korro Bio Trading Up 1.0 %

Shares of NASDAQ:KRRO opened at $15.56 on Thursday. The firm has a market capitalization of $146.12 million, a PE ratio of -1.65 and a beta of 2.66. Korro Bio has a 1-year low of $11.13 and a 1-year high of $98.00. The business’s 50 day moving average is $17.78 and its 200-day moving average is $34.55.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.60) by $0.11. The business had revenue of $2.55 million for the quarter, compared to analyst estimates of $0.13 million. On average, sell-side analysts predict that Korro Bio will post -9.52 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KRRO. KLP Kapitalforvaltning AS bought a new stake in Korro Bio during the 4th quarter worth about $53,000. AlphaQuest LLC grew its stake in shares of Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after purchasing an additional 412 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Korro Bio by 32.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock valued at $129,000 after purchasing an additional 831 shares in the last quarter. Deutsche Bank AG raised its position in Korro Bio by 29.4% in the 4th quarter. Deutsche Bank AG now owns 4,110 shares of the company’s stock worth $156,000 after purchasing an additional 935 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in Korro Bio by 664.1% during the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company’s stock worth $165,000 after buying an additional 3,759 shares in the last quarter. 13.18% of the stock is owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).